Vicus Therapeutics Overview

  • Founded
  • 2005
  • Status
  • Out of Business
  • Employees
  • 5
  • Latest Deal Type
  • Out of Business

Vicus Therapeutics General Information


Provider of cancer treatment therapies intended to bring breakthrough immunotherapies to patients with cancer. The company's services mainly focus on offering a drug product that is controlled-release formulation of propranolol, a non-selective β-blocker, and etodolac, a COX-2 selective inhibitor, for combination with PD-1 inhibitors, enabling patients to get affordable access to lung cancer treatment therapies for advanced stage.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly Angel backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 55 Madison Avenue
  • Suite 400
  • Morristown, NJ 07960
  • United States
+1 (973) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vicus Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Out of Business 01-Feb-2019 00.000 Completed Out of Business
4. Angel (individual) 12-Aug-2010 00000 00.000 Completed Startup
3. Angel (individual) 09-Jul-2009 00000 00.000 Completed Startup
2. Angel (individual) 06-Aug-2008 $800K $1.6M Completed Startup
1. Angel (individual) 27-Jul-2007 $800K $800K Completed Startup
To view Vicus Therapeutics’s complete valuation and funding history, request access »

Vicus Therapeutics Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial